1qf0 Citations

Crystal structures of alpha-mercaptoacyldipeptides in the thermolysin active site: structural parameters for a Zn monodentation or bidentation in metalloendopeptidases.

Biochemistry 38 12569-76 (1999)
Related entries: 1lna, 1lnb, 1lnc, 1lnd, 1lne, 1lnf, 1qf1, 1qf2

Cited: 28 times
EuropePMC logo PMID: 10504225

Abstract

Three alpha-mercaptoacyldipeptides differing essentially in the size of their C-terminal residues have been crystallized in the thermolysin active site. A new mode of binding was observed for 3 [HS-CH(CH(2)Ph)CO-Phe-Tyr] and 4 [HS-CH((CH(2))(4)CH(3))CO-Phe-Ala], in which the mercaptoacyl moieties act as bidentates with Zn-S and Zn-O distances of 2.3 and 2.4 A, respectively, the side chains fitting the S(1), S(1)', and S(2)' pockets. Moreover, a distance of 3.1 A between the sulfur atom and the OE1 of Glu(143) suggests that they are H-bonded and that one of these atoms is protonated. This H-bond network involving Glu(143), the mercaptoacyl group of the inhibitor, and the Zn ion could be considered a "modified" transition state mimic of the peptide bond hydrolysis. Due to the presence of the hindering (5-phenyl)proline, the inhibitor HS-CH(CH(2)Ph)CO-Gly-(5-Ph)Pro (2) interacts through the usual Zn monodentation via the thiol group and occupancy of S(1)' and S(2)' subsites by the aromatic moieties, the proline ring being outside the active site. The inhibitory potencies are consistent with these structural data, with higher affinities for 3 (4.2 x 10(-)(8) M) and 4 (4.8 x 10(-)(8) M) than for 2 (1.2 x 10(-)(6) M). The extension of the results, obtained with thermolysin being considered as the model of physiological zinc metallopeptidases, allows inhibitor-recognition modes for other peptidases, such as angiotensin converting enzyme and neutral endopeptidase, to be proposed and opens interesting possibilities for the design of new classes of inhibitors.

Articles - 1qf0 mentioned but not cited (4)

  1. Assessment of programs for ligand binding affinity prediction. Kim R, Skolnick J. J Comput Chem 29 1316-1331 (2008)
  2. An In Silico Target Fishing Approach to Identify Novel Ochratoxin A Hydrolyzing Enzyme. Dellafiora L, Gonaus C, Streit B, Galaverna G, Moll WD, Vogtentanz G, Schatzmayr G, Dall'Asta C, Prasad S. Toxins (Basel) 12 E258 (2020)
  3. Extrapolative prediction using physically-based QSAR. Cleves AE, Jain AN. J Comput Aided Mol Des 30 127-152 (2016)
  4. Elucidating the multiple roles of hydration for accurate protein-ligand binding prediction via deep learning. Mahmoud AH, Masters MR, Yang Y, Lill MA. Commun Chem 3 19 (2020)


Reviews citing this publication (1)

  1. The thermolysin family (M4) of enzymes: therapeutic and biotechnological potential. Adekoya OA, Sylte I. Chem Biol Drug Des 73 7-16 (2009)

Articles citing this publication (23)

  1. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. Oefner C, D'Arcy A, Hennig M, Winkler FK, Dale GE. J Mol Biol 296 341-349 (2000)
  2. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Turk BE, Wong TY, Schwarzenbacher R, Jarrell ET, Leppla SH, Collier RJ, Liddington RC, Cantley LC. Nat Struct Mol Biol 11 60-66 (2004)
  3. Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. Khan MT, Orhan I, Senol FS, Kartal M, Sener B, Dvorská M, Smejkal K, Slapetová T. Chem Biol Interact 181 383-389 (2009)
  4. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. Bernardo MM, Brown S, Li ZH, Fridman R, Mobashery S. J Biol Chem 277 11201-11207 (2002)
  5. Dissecting the hydrophobic effect on the molecular level: the role of water, enthalpy, and entropy in ligand binding to thermolysin. Biela A, Nasief NN, Betz M, Heine A, Hangauer D, Klebe G. Angew Chem Int Ed Engl 52 1822-1828 (2013)
  6. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. Patel Y, Gillet VJ, Bravi G, Leach AR. J Comput Aided Mol Des 16 653-681 (2002)
  7. A practical approach to docking of zinc metalloproteinase inhibitors. Hu X, Balaz S, Shelver WH. J Mol Graph Model 22 293-307 (2004)
  8. Binding of D- and L-captopril inhibitors to metallo-beta-lactamase studied by polarizable molecular mechanics and quantum mechanics. Antony J, Gresh N, Olsen L, Hemmingsen L, Schofield CJ, Bauer R. J Comput Chem 23 1281-1296 (2002)
  9. Modeling of metal interaction geometries for protein-ligand docking. Seebeck B, Reulecke I, Kämper A, Rarey M. Proteins 71 1237-1254 (2008)
  10. Metallotherapeutics: novel strategies in drug design. Hocharoen L, Cowan JA. Chemistry 15 8670-8676 (2009)
  11. The effects of modifying the surface charge on the catalytic activity of a thermolysin-like protease. de Kreij A, van den Burg B, Venema G, Vriend G, Eijsink VG, Nielsen JE. J Biol Chem 277 15432-15438 (2002)
  12. Crystal structure of Mycobacterium tuberculosis zinc-dependent metalloprotease-1 (Zmp1), a metalloprotease involved in pathogenicity. Ferraris DM, Sbardella D, Petrera A, Marini S, Amstutz B, Coletta M, Sander P, Rizzi M. J Biol Chem 286 32475-32482 (2011)
  13. Copper-catalyzed enantioselective carbenoid insertion into S-H bonds. Zhang YZ, Zhu SF, Cai Y, Mao HX, Zhou QL. Chem Commun (Camb) 5362-5364 (2009)
  14. Exploring the influence of the protein environment on metal-binding pharmacophores. Martin DP, Blachly PG, McCammon JA, Cohen SM. J Med Chem 57 7126-7135 (2014)
  15. 'Unconventional' coordination chemistry by metal chelating fragments in a metalloprotein active site. Martin DP, Blachly PG, Marts AR, Woodruff TM, de Oliveira CA, McCammon JA, Tierney DL, Cohen SM. J Am Chem Soc 136 5400-5406 (2014)
  16. Homology modeling of hemagglutinin/protease [HA/P (vibriolysin)] from Vibrio cholerae: sequence comparision, residue interactions and molecular mechanism. Lutfullah G, Amin F, Khan Z, Azhar N, Azim MK, Noor S, Shoukat K. Protein J 27 105-114 (2008)
  17. The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor. Kostenko S, Khan MT, Sylte I, Moens U. Cell Mol Life Sci 68 289-301 (2011)
  18. Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme. Sharma U, Cozier GE, Sturrock ED, Acharya KR. J Med Chem 63 5488-5500 (2020)
  19. Coordination and thermodynamics of stable Zn(II) complexes in the gas phase. Smiesko M, Remko M. J Biomol Struct Dyn 20 759-770 (2003)
  20. Stimulation and oxidative catalytic inactivation of thermolysin by copper.Cys-Gly-His-Lys. Gokhale NH, Bradford S, Cowan JA. J Biol Inorg Chem 12 981-987 (2007)
  21. A new class of potent reversible inhibitors of metallo-proteinases: C-terminal thiol-peptides as zinc-coordinating ligands. Peters K, Jahreis G, Kotters EM. J Enzyme Inhib 16 339-350 (2001)
  22. QM/MM investigation of the catalytic mechanism of angiotensin-converting enzyme. Mu X, Zhang C, Xu D. J Mol Model 22 132 (2016)
  23. The Drosophila melanogaster Neprilysin Nepl15 is involved in lipid and carbohydrate storage. Banerjee S, Woods C, Burnett M, Park SJ, Ja WW, Curtiss J. Sci Rep 11 2099 (2021)


Related citations provided by authors (4)

  1. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.. Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, Michel JB, Roques BP J Med Chem 39 2594-608 (1996)
  2. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.. Coric P, Turcaud S, Meudal H, Roques BP, Fournie-Zaluski MC J Med Chem 39 1210-9 (1996)
  3. Structural analysis of zinc substitutions in the active site of thermolysin.. Holland DR, Hausrath AC, Juers D, Matthews BW Protein Sci 4 1955-65 (1995)
  4. Three-dimensional structure of thermolysin.. Matthews BW, Jansonius JN, Colman PM, Schoenborn BP, Dupourque D Nat New Biol 238 37-41 (1972)